Got this press release this morning. More options for people with diabetes in Canada!
Insulet Corporation and GlaxoSmithKline Inc. Sign Distribution
Agreement for the OmniPod Insulin Management System in Canada
Insulet’s Tubing-Free Insulin Pump to Be Available Across Canada for
the First Time BEDFORD, MA and TORONTO, Mar 02, 2011 (MARKETWIRE via
COMTEX) –
Insulet Corporation (“Insulet”) (NASDAQ: PODD), the leader in
tubing-free insulin pump technology with its OmniPod(R) Insulin
Management System, and GlaxoSmithKline Inc., one of the world’s
leading research-based pharmaceutical and healthcare companies, today
announced an exclusive distribution agreement for the OmniPod Insulin
Management System in Canada.
“We are very pleased to work with a leader like GlaxoSmithKline Inc.
to expand access to the OmniPod System to Canadians with diabetes,”
said Duane DeSisto, President and Chief Executive Officer of Insulet.
“The OmniPod’s tubing-free design and ease of use have provided
freedom to tens of thousands of people in the United States and
abroad. We look forward to the opportunity to positively impact the
lives of Canadians with insulin-dependent diabetes.”
“Partnering with Insulet to bring the OmniPod System to Canada
directly reflects our mission to enable people to do more, feel better
and live longer,” said Paul Lucas, President and CEO, GlaxoSmithKline
Inc. “As a patient-focused company with over a decade of experience in
diabetes care, we are proud that the availability of this system will
so significantly improve the management of diabetes for Canadian
patients, their families and caregivers.”
According to the agreement, GlaxoSmithKline Inc. will have exclusive
rights to promote, advertise, market, distribute and sell the OmniPod
System in Canada. Additional information for Canadian patients and
healthcare providers will soon be available at www.myomnipod.ca, which
is currently scheduled to launch in mid-March 2011.
About the OmniPod(R) Insulin Management System The OmniPod(R) Insulin
Management System is the world’s first tubing-free insulin pump.
OmniPod(R) offers people living with insulin-requiring diabetes all
the benefits of insulin pump therapy, with freedom, comfort and ease.
OmniPod(R) has just two components: the small, discreet, waterproof
Pod that can be worn on many parts of the body to hold and deliver
insulin; and the PDM (Personal Diabetes Manager), a hand-held device
that communicates wirelessly to program the Pod, calculates suggested
doses and has a built-in FreeStyle(R) blood glucose meter. For more
information, please visit: www.myomnipod.com (US residents only).
About Insulet Corporation Insulet Corporation is an innovative medical
device company dedicated to improving the lives of people with
diabetes. The company’s OmniPod(R) Insulin Management System is a
revolutionary, discreet and easy-to-use insulin infusion system that
features two easy-to-use parts with no tubing and fully-automated
cannula insertion. Through the OmniPod(R) System, Insulet seeks to
expand the use of continuous subcutaneous insulin infusion (CSII)
therapy among people with insulin-dependent diabetes. Founded in 2000,
Insulet Corporation is based in Bedford, Mass.
About GlaxoSmithKline Inc. GlaxoSmithKline Inc. (GSK) is a leading
research-based pharmaceutical company with a challenging and inspiring
mission: to improve the quality of human life by enabling people to do
more, feel better, and live longer. This mission gives GSK the purpose
to develop innovative medicines, vaccines and healthcare solutions
that help millions of people. GSK is consistently recognized as one of
the 50 best employers in Canada and is a top 15 investor in Canadian
research and development, contributing more than $144 million in 2009
alone. With a proud tradition of charitable and community support, GSK
is designated a Caring Company by Imagine Canada. Discover more at
GSK.ca.